Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade

A daily increase in the number of new cases of pancreatic ductal adenocarcinoma remains an issue of contention in cancer research. The data revealed that a global cumulated case of about 500, 000 have been reported. This has made PDAC the fourteenth most occurring tumor case in cancer research. Furt...

Full description

Bibliographic Details
Main Authors: Abdullahi Alausa, Khadijat Ayodeji Lawal, Oluwakemi Arinola Babatunde, E.N.O. Obiwulu, Olajumoke Christianah Oladokun, Olumide Samuel Fadahunsi, Ugwu Obiora Celestine, Emmanuel Ugbede Moses, Ifunanya Rejoice Akaniro, Peter Ifeoluwa Adegbola
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:Pharmacological Research
Subjects:
PDAC
Immunotherapy
CD47
SIRPα
Phagocytosis
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661822002092

Internet

http://www.sciencedirect.com/science/article/pii/S1043661822002092

Similar Items